Drugs / AK135
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06860789 | Feb 2025 → Mar 2026 overdue | chemotherapy-induced neuropathy | Akeso | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | Akeso | 康方生物IL-1RAP抗体（AK135）临床前数据在SITC2025发布，有望为CIPN提供新解决方案 akesobio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK135 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06860789 ↗ |
| Route | Intravenous | “IV infusion, specified dose with specified treatment frequency” NCT06860789 ↗ |